Pulse cyclophosphamide treatment for severe refractory cutaneous lupus erythematosus

Abstract

Cutaneous lupus erythematosus includes a variety of lupus erythematosus specific skin lesions that, in some cases, can be disfiguring and refractory to conventional therapy. This short report describes our experience in treating six patients with severe, refractory subacute cutaneous lupus erythematosus with monthly cyclophosphamide pulses, followed by azathioprine as maintenance therapy. Significant clinical improvement of the subacute cutaneous lupus erythematosus lesions was achieved in all patients, with four patients in complete remission and two in partial remission. Mean time to clinical response was 4.33 ± 1.36 months. Minor adverse events and no relapses were noted in a follow-up period of more than 3 years. Lupus (2010) 19, 744—747.

Keywords

cutaneous lupus subacute lupus erythematosus cyclophosphamide

Get full access to this article

View all access options for this article.

References

Laman SD , Provost TT Cutaneous manifestations of lupus erythematosus. Rheum Dis Clin North Am 1994; 20: 195-212.

Boumpas DT , Fessler B. , Austin H. , Balow JE , Klippel JH , Lockshin MD Systemic lupus erythematosus: emerging concepts: Part 2: Dermatologic and joint disease, the antiphospholipid syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 1995; 123: 42-53.

Duna FG , Cash JM Treatment of refractory cutaneous lupus erythematosus. Rheum Dis Clin North Am 1995; 21: 99-115.

Ting WW , Sontheimer RD Local therapy for cutaneous and systemic lupus erythematosus: practical and theoretical considerations. Lupus 2001 ; 10: 171-184.

Jessop S. , Whitelas D. , Jordaan F. Drugs for discoid lupus erythematosus. Cochrane Database Syst Rev 2001; 1: CD002954.

Callen JP Management of skin disease in patients with lupus erythematosus. Best Pract Res Clin Rheumatol 2002; 16: 245-260.

Cuadrado MJ , Karim Y. , Sanna G. , Smith E. , Khamashta MA , Hughes GR Thalidomide for the treatment of resistant cutaneous lupus: Efficacy and safety of different therapeutic regimens. Am J Med 2005; 118: 246-250.

Tassioulas I. , Boumpas DT Clinical features and treatment of systemic lupus erythematosus. In Kelley’s Textbook of Rheumatology , 8th edn. Philadelphia, PA: Saunders-Elsevier; 2009. p. 1263-1300.

Wenzel J. , Brähler S. , Bauer R. , Bieber T. , Tüting T. Efficacy and safety of methotrexate in recalcitrant cutaneous lupus erythematosus: results of a retrospective study in 43 patients. Br J Dermatol 2005; 153: 157-162.

10.

Schanz S. , Ulmer A. , Rassner G. , Fierlbeck G. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 2002; 147: 174-178.

11.

Callen JP , Spencer LV , Burruss JB , Holtman J. Azathioprine: an effective, corticosteroids-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leucocytoclastic vasculitis. Arch Dermatol 1991; 127: 515-522.

12.

Takada K. , Illei GG , Boumpas DT Cyclophosphamide for the treatment of systemic lupus erythematosus . Lupus 2001; 10: 154-161.

13.

Albrecht J. , Taylor L. , Berlin JA , et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005; 125: 889-894.

14.

Raptopoulou A. , Sidiropoulos P. , Boumpas D. Ovarian failure and strategies for fertility preservation in patients with systemic lupus erythematosus . Lupus 2004; 13: 887-890.

15.

Basra MK , Shahrukh M. Burden of skin diseases. Expert Rev Pharmacoecon Outcomes Res 2009; 9: 271-283.